Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
656 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02211131 | Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma | completed | Phase 2 | 150 | AmgenINDUSTRY | 9 | Jun 5, 2023 | clinicaltrials |
| NCT02879682 | nTMS for Motor Mapping of Rolandic Lesions(Motorstim) | completed | Phase 2 / Phase 3 | 330 | Technical University of MunichOTHER | 3 | Jun 1, 2023 | clinicaltrials |
| NCT04933942 | Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma(RIGOLETTO) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | May 24, 2023 | clinicaltrials |
| NCT02895360 | Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 43 | Basilea PharmaceuticaINDUSTRY | 1 | May 10, 2023 | clinicaltrials |
| NCT00268476 | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy(STAMPEDE) | active not recruiting | Phase 2 / Phase 3 | 11,992 | Medical Research CouncilOTHER_GOV | 2 | Apr 18, 2023 | clinicaltrials |
| NCT02371447 | VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 2 | Apr 13, 2023 | clinicaltrials |
| NCT01040026 | Expanded Natural Killer (NK) Cells for Multiple Myeloma Study | completed | Phase 1 / Phase 2 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03238599 | Pedometer Activity Monitoring After ASCT(PAMAL) | completed | Phase 2 | 62 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03132675 | Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment(Keynote-695) | unknown | Phase 2 | 143 | OncoSec Medical IncorporatedINDUSTRY | 5 | Mar 27, 2023 | clinicaltrials |
| NCT02659384 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | completed | Phase 2 | 122 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Mar 14, 2023 | clinicaltrials |
| NCT02598960 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | completed | Phase 1 / Phase 2 | 295 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 6, 2023 | clinicaltrials |
| NCT02454972 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | completed | Phase 2 | 345 | PharmaMarINDUSTRY | 9 | Mar 2, 2023 | clinicaltrials |
| NCT03251924 | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 80 | Bristol-Myers SquibbINDUSTRY | 4 | Feb 28, 2023 | clinicaltrials |
| NCT03386721 | Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors | terminated | Phase 2 | 256 | Hoffmann-La RocheINDUSTRY | 15 | Feb 21, 2023 | clinicaltrials |
| NCT03534635 | Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) | unknown | Phase 2 | 30 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT01714739 | A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 337 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 2, 2023 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT03762122 | Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) | terminated | Phase 2 | 15 | Swiss Cancer InstituteOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 53 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 10, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT03524898 | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | terminated | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04529850 | Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer | completed | Phase 2 | 38 | Galera Therapeutics, Inc.INDUSTRY | 6 | Aug 16, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT05468294 | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer(Nivokin) | unknown | Phase 1 / Phase 2 | 3 | Philogen S.p.A.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | terminated | Phase 1 / Phase 2 | 33 | Swiss Cancer InstituteOTHER | 2 | Jul 7, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT02183870 | EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer(EUCROSS) | completed | Phase 2 | 34 | University of CologneOTHER | 3 | Jun 16, 2022 | clinicaltrials |
| NCT01887522 | Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults(VINILO) | terminated | Phase 2 | 144 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 8 | May 31, 2022 | clinicaltrials |
| NCT03101475 | Synergism of Immunomodulation and Tumor Ablation(ILOC) | completed | Phase 2 | 22 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 31, 2022 | clinicaltrials |
| NCT03494205 | Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis(Urticacomp) | completed | Phase 2 | 31 | University of BernOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT04264806 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | withdrawn | Phase 2 | 0 | Janssen Research & Development, LLCINDUSTRY | 11 | May 20, 2022 | clinicaltrials |
| NCT02945813 | SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy | terminated | Phase 2 | 112 | Swiss Cancer InstituteOTHER | 3 | Apr 14, 2022 | clinicaltrials |
| NCT04125693 | Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety | completed | Phase 2 | 1 | BayerINDUSTRY | 1 | Apr 1, 2022 | clinicaltrials |
| NCT04614493 | Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.(SonoFIRST) | unknown | Phase 2 | 66 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Mar 29, 2022 | clinicaltrials |
| NCT01059188 | Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 69 | Swiss Cancer InstituteOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 58 | Swiss Cancer InstituteOTHER | 3 | Mar 11, 2022 | clinicaltrials |
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | terminated | Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 8 | Feb 28, 2022 | clinicaltrials |
| NCT03794544 | Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | completed | Phase 2 | 84 | MedImmune LLCINDUSTRY | 7 | Feb 24, 2022 | clinicaltrials |
| NCT04109755 | Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer(PEMREC) | recruiting | Phase 2 | 25 | University Hospital, GenevaOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT01644994 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 47 | University of ZurichOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02404506 | Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer | terminated | Phase 2 | 78 | Swiss Cancer InstituteOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02833766 | Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer | terminated | Phase 2 | 48 | Swiss Cancer InstituteOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT03563040 | Study of Photopheresis in the Treatment of Erythrodermic MF and SS(PROMPT) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 8, 2021 | clinicaltrials |
| NCT00425555 | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma | completed | Phase 2 | 139 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 20, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00003338 | Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | unknown | Phase 2 / Phase 3 | 60 | Gilead SciencesINDUSTRY | 5 | Aug 16, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | completed | Phase 1 / Phase 2 | 105 | Bristol-Myers SquibbINDUSTRY | 9 | Jul 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials